Development of Targeted Adjuvants for HIV-1 Vaccines

Overview

Journal AIDS Res Ther

Publisher Biomed Central

Specialty Infectious Diseases

Date 2017 Sep 13

PMID 28893282

Citations 7

Authors

Jun Liu

Mario Ostrowski

Affiliations

Soon will be listed here.

Abstract

Finding new adjuvants is an integrated component of the efforts in developing an effective HIV-1 vaccine. Compared with traditional adjuvants, a modern adjuvant in the context of HIV-1 prevention would elicit a durable and potent memory response from B cells, CD8 T cells, and NK cells but avoid overstimulation of HIV-1 susceptible CD4 T cells, especially at genital and rectal mucosa, the main portals for HIV-1 transmission. We briefly review recent advances in the studies of such potential targeted adjuvants, focusing on three classes of molecules that we study: TNFSF molecules, TLRs agonists, and NODs agonists.

Citing Articles

Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects.

Kaur A, Vaccari M Viruses. 2024; 16(3).

PMID: 38543734 PMC: 10974975. DOI: 10.3390/v16030368.

An MVA-based vector expressing cell-free ISG15 increases IFN-I production and improves HIV-1-specific CD8 T cell immune responses.

Falqui M, Perdiguero B, Coloma R, Albert M, Marcos-Villar L, McGrail J Front Cell Infect Microbiol. 2023; 13:1187193.

PMID: 37313341 PMC: 10258332. DOI: 10.3389/fcimb.2023.1187193.

Identification of prognostic and predictive biomarkers in high-dimensional data with PPLasso.

Zhu W, Levy-Leduc C, Ternes N BMC Bioinformatics. 2023; 24(1):25.

PMID: 36690931 PMC: 9869528. DOI: 10.1186/s12859-023-05143-0.

Preventive HIV Vaccines-Leveraging on Lessons from the Past to Pave the Way Forward.

Sobia P, Archary D Vaccines (Basel). 2021; 9(9).

PMID: 34579238 PMC: 8472969. DOI: 10.3390/vaccines9091001.

Enhancement of HIV-1 Env-Specific CD8 T Cell Responses Using Interferon-Stimulated Gene 15 as an Immune Adjuvant.

Gomez C, Perdiguero B, Falqui M, Marin M, Becares M, Sorzano C J Virol. 2020; 95(2).

PMID: 33115866 PMC: 7944454. DOI: 10.1128/JVI.01155-20.

References

Yates N, Liao H, Fong Y, deCamp A, Vandergrift N, Williams W . Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med. 2014; 6(228):228ra39. PMC: 4116665. DOI: 10.1126/scitranslmed.3007730. View

Sundling C, Martinez P, Soldemo M, Spangberg M, Lovgren Bengtsson K, Stertman L . Immunization of macaques with soluble HIV type 1 and influenza virus envelope glycoproteins results in a similarly rapid contraction of peripheral B-cell responses after boosting. J Infect Dis. 2012; 207(3):426-31. DOI: 10.1093/infdis/jis696. View

Belnoue E, Pihlgren M, McGaha T, Tougne C, Rochat A, Bossen C . APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood. 2008; 111(5):2755-64. DOI: 10.1182/blood-2007-09-110858. View

Bossen C, Schneider P . BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol. 2006; 18(5):263-75. DOI: 10.1016/j.smim.2006.04.006. View

Robb M, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P . Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis. 2012; 12(7):531-7. PMC: 3530398. DOI: 10.1016/S1473-3099(12)70088-9. View

Chun T, Engel D, Berrey M, Shea T, Corey L, Fauci A . Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A. 1998; 95(15):8869-73. PMC: 21169. DOI: 10.1073/pnas.95.15.8869. View

Gupta S, Clark E, Termini J, Boucher J, Kanagavelu S, LeBranche C . DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers. J Virol. 2015; 89(8):4158-69. PMC: 4442371. DOI: 10.1128/JVI.02904-14. View

Ding Y, Liu J, Lu S, Igweze J, Xu W, Kuang D . Self-assembling peptide for co-delivery of HIV-1 CD8+ T cells epitope and Toll-like receptor 7/8 agonists R848 to induce maturation of monocyte derived dendritic cell and augment polyfunctional cytotoxic T lymphocyte (CTL) response. J Control Release. 2016; 236:22-30. DOI: 10.1016/j.jconrel.2016.06.019. View

Kwa S, Sadagopal S, Shen X, Hong J, Gangadhara S, Basu R . CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus (SIV) vaccine enhances protection against neutralization-resistant mucosal SIV infection. J Virol. 2015; 89(8):4690-5. PMC: 4442387. DOI: 10.1128/JVI.03527-14. View

10.

Moodie Z, Metch B, Bekker L, Churchyard G, Nchabeleng M, Mlisana K . Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. PLoS One. 2015; 10(9):e0137666. PMC: 4569275. DOI: 10.1371/journal.pone.0137666. View

11.

Fritz J, Le Bourhis L, Sellge G, Gamelas Magalhaes J, Fsihi H, Kufer T . Nod1-mediated innate immune recognition of peptidoglycan contributes to the onset of adaptive immunity. Immunity. 2007; 26(4):445-59. DOI: 10.1016/j.immuni.2007.03.009. View

12.

Bonsignori M, Moody M, Parks R, Holl T, Kelsoe G, Hicks C . HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J Immunol. 2009; 183(4):2708-17. PMC: 3089979. DOI: 10.4049/jimmunol.0901068. View

13.

OConnor B, Raman V, Erickson L, Cook W, Weaver L, Ahonen C . BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004; 199(1):91-8. PMC: 1887725. DOI: 10.1084/jem.20031330. View

14.

Buchbinder S, Mehrotra D, Duerr A, Fitzgerald D, Mogg R, Li D . Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008; 372(9653):1881-1893. PMC: 2721012. DOI: 10.1016/S0140-6736(08)61591-3. View

15.

Barouch D, Stephenson K, Borducchi E, Smith K, Stanley K, McNally A . Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell. 2013; 155(3):531-9. PMC: 3846288. DOI: 10.1016/j.cell.2013.09.061. View

16.

Kwa S, Lai L, Gangadhara S, Siddiqui M, Pillai V, LaBranche C . CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge. J Virol. 2014; 88(17):9579-89. PMC: 4136340. DOI: 10.1128/JVI.00975-14. View

17.

Kasturi S, Kozlowski P, Nakaya H, Burger M, Russo P, Pham M . Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques. J Virol. 2016; 91(4). PMC: 5286877. DOI: 10.1128/JVI.01844-16. View

18.

Gosselin A, Wiche Salinas T, Planas D, Wacleche V, Zhang Y, Fromentin R . HIV persists in CCR6+CD4+ T cells from colon and blood during antiretroviral therapy. AIDS. 2016; 31(1):35-48. PMC: 5131694. DOI: 10.1097/QAD.0000000000001309. View

19.

Moody M, Santra S, Vandergrift N, Sutherland L, Gurley T, Drinker M . Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. J Virol. 2014; 88(6):3329-39. PMC: 3957956. DOI: 10.1128/JVI.03309-13. View

20.

Liu J, Ostrowski M . Development of TNFSF as molecular adjuvants for ALVAC HIV-1 vaccines. Hum Vaccin. 2010; 6(4):355-9. DOI: 10.4161/hv.6.4.10867. View